Roughening and preroughening in the six vertex model with an extended range of interaction

We study the phase diagram of the BCSOS model with an extended interaction range using transfer matrix techniques, pertaining to the (100) surface of single component fcc and bcc crystals. The model shows a 2x2 reconstructed phase and a disordered flat phase. The deconstruction transition between these phases merges with a Kosterlitz-Thouless line, showing an interplay of Ising and Gaussian degrees of freedom. As in studies of the fully frustrated XY model, exponents deviating from Ising are found. We conjecture that tri-critical Ising behavior may be a possible explanation for the non-Ising exponents found in those models.Comment: 25 pages in RevTeX 3.0, seven uuencoded postscript figures, REPLACED because of submission error (figures were not included

Is surface melting a surface phase transition?

Monte Carlo or Molecular Dynamics calculations of surfaces of Lennard-Jones systems often indicate, apart from a gradual disordering of the surface called surface melting, the presence of a phase transition at the surface, but cannot determine the nature of the transition. In the present paper, we provide for a link between the continuous Lennard-Jones system and a lattice model. We apply the method for the (001) surface of a Lennard-Jones fcc structure pertaining to Argon. The corresponding lattice model is a Body Centered Solid on Solid model with an extended range of interaction, showing in principle rough, flat and disordered flat phases. We observe that entropy effects considerably lower the strength of the effective couplings between the atoms. The Argon (001) face is shown to exhibit a phase transition at T=70.5 +- 0.5 K, and we identify this transition as roughening. The roughening temperature is in good correspondence with experimental results for Argon.Comment: 17 pages REVTeX, 14 uuencoded postscript figures appende

Detection of endo-epicardial atrial low-voltage areas using unipolar and omnipolar voltage mapping

Background: Low-voltage areas (LVA) can be located exclusively at either the endocardium or epicardium. This has only been demonstrated for bipolar voltages, but the value of unipolar and omnipolar voltages recorded from either the endocardium and epicardium in predicting LVAs at the opposite layer remains unknown. The goal of this study was therefore to compare simultaneously recorded endo-epicardial unipolar and omnipolar potentials and to determine whether their voltage characteristics are predictive for opposite LVAs. Methods: Intra-operative simultaneous endo-epicardial mapping (256 electrodes, interelectrode distances 2 mm) was performed during sinus rhythm at the right atrium in 93 patients (67 ± 9 years, 73 male). Cliques of four electrodes (2 × 2 mm) were used to define maximal omnipolar (V(omni,max)) and unipolar (V(uni,max)) voltages. LVAs were defined as V(omni,max) ≤0.5 mV or V(uni,max) ≤1.0 mV. Results: The majority of both unipolar and omnipolar LVAs were located at only the endocardium (74.2% and 82.0% respectively) or epicardium (52.7% and 47.6% respectively). Of the endocardial unipolar LVAs, 25.8% were also located at the opposite layer and 47.3% vice-versa. In omnipolar LVAs, 18.0% of the endocardial LVAs were also located at the epicardium and 52.4% vice-versa. The combination of epicardial V(uni,max) and V(omni,max) was most accurate in identifying dual-layer LVAs (50.4%). Conclusion: Unipolar and omnipolar LVAs are frequently located exclusively at either the endocardium or epicardium. Endo-epicardial LVAs are most accurately identified using combined epicardial unipolar and omnipolar voltages. Therefore, a combined endo-epicardial unipolar and omnipolar mapping approach is favoured as it may be more indicative of possible arrhythmogenic substrates

The HF-AF ENERGY Trial:Nicotinamide Riboside for the Treatment of Atrial Fibrillation in Heart Failure Patients

Background: The presence of atrial fibrillation (AF) in heart failure (HF) patients with reduced ejection fraction is common and associated with an increased risk of stroke, hospitalization and mortality. Recent research findings indicate that a reduction in nicotinamide adenine dinucleotide (NAD+) levels results in mitochondrial dysfunction, DNA damage and consequently cardiomyocyte impairment in experimental and clinical HF and AF. The HF-AF ENERGY trial aims to investigate the cardioprotective effects of the NAD+ precursor nicotinamide riboside (NR) treatment in ischemic heart disease patients diagnosed with AF. Study design: The HF-AF ENERGY trial is a prospective intervention study. The study consists of a (retrospective) 4 months observation period and a 4 months intervention period. The cardioprotective effect of NR on AF burden is investigated by remote monitoring software of implantable cardiac defibrillators (ICDs), which enables continuous atrial rhythm monitoring detection. Cardiac dimension and function are examined by echocardiography. Laboratory blood analysis is performed to determine mitochondrial function markers and energy metabolism. All the study parameters are assessed at two fixed time points (pre- and post-treatment). Pre- and post-treatment outcomes are compared to determine the effects of NR treatment on AF burden, mitochondrial function markers and energy metabolism. Conclusion: The HF-AF ENERGY trial investigates the cardioprotective effects of NR on AF burden and whether NR normalizes blood-based mitochondrial function markers and energy metabolites of the NAD metabolome in ischemic heart disease patients diagnosed with AF. The study outcomes elucidate whether NAD+ metabolism can be used as a future therapy for HF patients with AF.</p